Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Resectable HER2-positive Breast Cancer × Epirubicin × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Non-Muscle Invasive Bladder Neoplasms 1 Breast Neoplasms 1

Interventions

pertuzumab 1 Trastuzumab 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Shanghai JMT-Bio Inc.

Phase 3 Not yet recruiting

Resectable HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡